SCHEMBL23219170

SCHEMBL23219170

CCOC(=O)c1ccccc1OCc1nn(C(C)C)c2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 3/20 0.46
PLG P00747 2/20 0.39
PLAU P00749 2/20 0.39
F11 P03951 2/20 0.39
TPSB2 P20231 2/20 0.39
KLKB1 P03952 1/20 0.39
F7 P08709 1/20 0.39
PPIA P62937 1/20 0.37
HTT P42858 1/20 0.36
TBXAS1 P24557 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
SCN9A Q15858 1/20 0.35
PTGES O14684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219231 0.90 PLG (0.46) CFDPLGPLAUF11TPSB2
SCHEMBL29853182 0.87 CFD (0.62) CFDPLGPLAUF11TPSB2
SCHEMBL23219243 0.87 CFD (0.62) CFDPLGPLAUF11TPSB2
SCHEMBL23219193 0.85 CFD (0.43) CFDPLGPLAUF11TPSB2
SCHEMBL29852818 0.85 CFD (0.43) CFDPLGPLAUF11TPSB2
SCHEMBL29852616 0.84 CFD (0.42) CFDPLGPLAUF11TPSB2
SCHEMBL23219138 0.84 CFD (0.42) CFDPLGPLAUF11TPSB2
SCHEMBL29593174 0.83 CFD (0.62) CFDPLGPLAUF11TPSB2
SCHEMBL23219211 0.83 CFD (0.62) CFDPLGPLAUF11TPSB2
SCHEMBL23219126 0.82 ELANE (0.46) PPIATBXAS1CYP1A2POLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLG 421/4885PLAU 1119/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLG 89/4885PLAU 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.